Feed Top Reports Pricing

⌘K

08:55:08·42d

ANALYSTRating

Oppenheimer resumed coverage on ProQR Therapeutics with a new price target

PRQR· ProQR Therapeutics N.V.

Health Care

Original source

Companies

PRQR
ProQR Therapeutics N.V.
Health Care

Recent analyst ratings

Mar 12UpdateOppenheimer$9.00
Apr 29UpdateEvercore ISI$5.00
Apr 29UpdateCantor Fitzgerald$8.00
Mar 10UpdateCitigroup$4.00
Jan 10UpdateOppenheimer$15.00
Oct 29UpdateRaymond James$14.00

Related

SEC15d
SEC Form 6-K filed by ProQR Therapeutics N.V.
PR15d
ProQR Highlights Pipeline Expansion and Multiple Upcoming Clinical Catalysts at Investor and Analyst Event
SEC16d
SEC Form 6-K filed by ProQR Therapeutics N.V.
PR16d
ProQR Announces Partnership with Ginkgo Bioworks and Formation of AI Advisory Board
SEC30d
SEC Form 6-K filed by ProQR Therapeutics N.V.
PR30d
ProQR to Host Virtual Investor and Analyst Event Highlighting Pipeline on April 8, 2026
INSIDER36d
SEC Form 3 filed by new insider Valerio Domenico
INSIDER36d
SEC Form 3 filed by new insider Platenburg Gerardus Johannes

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releases Analyst ratings Insider trading FDA SEC RSS feeds

Top lists

Trending By market cap Active companies Analyst upgrades Insider purchases FDA approvals SEC filings Sectors Market reports

Company

About Pricing Publish with us Contact

Legal

Terms of use Privacy policy Cookie policy

© 2026 quantisnow.com · Democratizing insights since 2022